Business
Roche’s Kidney Drug Posts Positive Phase 3 Data in a Crowding IgA Nephropathy Race
Sefaxersen significantly cut a key marker of kidney damage in a rare disease that has suddenly attracted a wave of new treatments — and Roche is betting a once-monthly, at-home injection can stand out.